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Abstract Increasing evidence is showing that the non-
neuronal cholinergic system plays an important role in the
pathology of rheumatoid arthritis (RA). Choline transport into
the cell is the rate-limiting step for the synthesis of acetylcho-
line (ACh), which can be released directly or in vesicles from
the cell. However, in the human joint little is known about
choline import or the release of ACh from the cell. Thus,
we analyze the expression of members of the organic cation
transporter (OCT), of the newly discovered choline
transporter-like (CTL) family and of classical neuronal com-
ponents such as the high-affinity choline transporter (CHT1)
and the vesicular ACh transporter (VAChT) in the
synovium and cartilage of the human hip joint from patients
with osteoarthritis (OA) and RA. OCT1, OCT3 and
OCTN1 and all members of the CTL family were expressed
in synovial and cartilage samples. The expression of CTL1
and CTL2 was localized in synovial macrophages and
fibroblasts. CHT1 mRNA expression was detectable only
in the synovium, whereas VAChT was completely absent in
all samples. Therefore, in the human joint, choline transport
into the cell and the release of ACh seems to be mediated
mainly by members of the OCT and CTL family. Expres-
sion of transporters appears not to be influenced by the
pathological state, as no differences have been detected
between joints from OA or RA patients. Importantly, how-
ever, all necessary components for choline import and the
release of non-neuronal ACh are present in the human joint.
Keywords Rheumatoid arthritis . Non-neuronal cholinergic
system . Acetylcholine . Choline transporter-like proteins .
Organic cation transporter . Human
Introduction
Acetylcholine (ACh) is commonly known as a neurotransmit-
ter. Nevertheless, increasing research has recently concentrat-
ed on the importance of ACh as a signaling molecule in non-
neuronal cells in which it can play a role in regulating various
biological functions (Beckmann and Lips 2013). ACh exerts
its functions by acting on muscarinic and nicotinic receptors
present on effector cells. The expression of these receptors is,
however, not an indication for the existence of a non-neuronal
cholinergic system (NNCS) which is characterized by the
ability of the cell to produce and release ACh. The synthesis
of ACh from choline and acetyl coenzyme A is facilitated by
the enzyme choline acetyltransferase (ChAT; Wessler et al.
2003). In some non-neuronal cells, ACh can alternatively be
produced by carnitin acetyltransferase (CarAT; Lips et al.
2007; Tucek 1982). The uptake of choline into the cell is
one of the essential and rate-limiting factors for the synthesis
of ACh. Choline is a positively charged quaternary amine that
requires carrier-mediated transport into the cell. The high-
affinity choline transporter (CHT1) is the transporter with
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the highest affinity for choline and is Na+- and Cl−-dependent.
CHT1 is required for choline uptake in neuronal cells and
without CHT1, neurons are unable to synthesize ACh
(Ferguson et al. 2004). Even though some non-neuronal cells
have been shown to express CHT1 (Lips et al. 2003; Pfeil
et al. 2003), many non-neuronal cells that synthesize ACh do
not express this transporter, indicating that other mechanisms
of choline transport must exist. Notably, members of Na+-
independent polyspecific organic cation transporters (OCT1-
3) of the solute carrier protein (SLC) 22 family have been
shown to have low affinity for choline (Koepsell 2004).
Choline can be taken up by OCT1 and by OCT2. OCT3,
however seems not to be able to recognize choline as a
substrate (Busch et al. 1996; Sweet et al. 2001). Recently,
the family of choline transporter-like (CTL) proteins has been
identified as Na+-independent transporters with intermediate
affinity for choline (O'Regan et al. 2000). To date, five mem-
bers of this transporter family, CTL1-5, have been identified
(Traiffort et al. 2005) but have not been extensively studied as
yet. The best-characterized member CTL1 shows ubiquitous
expression (Michel and Bakovic 2012) and CTL1-dependent
choline transport has been described in many different cell
Table 1 Human primer pairs used for qualitative an real-time RT-PCR (CHT high-affinity choline transporter, CTL choline transporter-like, OCTN
organic cation transporters novel, OCT organic cation transporter, VAChT vesicular acetylcholine transporter, βMG β2-microglobulin)
Gene Primer sequence Length (bp) Annealing temperature (°C) Accession number
CHT1 ATCCCAGCCATACTCATT 168 59 NM_021815.2
CAGAAACTGCACCAAGACCA
CTL1 GTTCACTTGGAGGCACAGGT 206 62 BC049203.1
GGCGATGGTAAGAGCAACAC
CTL2 AAACCCTTGGCCCGGAGATGCT 160 62 BC040556.1
GCCGCGCCTCTAGGACTCCAT
CTL3 TCCTTGGCCTGTGTATCCTCGCA 130 62 AL540829
ACACCGCAGACAAACAACAATCCCA
CTL4 TGCCTACTGGGCCATGACTGCT 138 62 BC014659
ACAAGGTGGGCCGTGGGGTT
CTL5 CTGCTGAAGGAAGGAAGCAAAGCCA 138 62 BC051740
AGGTACCCCCGATGTCGCCAA
OCTN1 CTGTGGAGGAGCTAAATCCCCTGAA 149 59 BC028313
AGGAGCATCCAGAGACAGAGCAA
OCT1 GACGCCGAGAACCTTGGG 198 55 NM_003057
GGGTAGGCAAGTATGAGG
OCT2 TCGTCCATCGTCACCGAGT 302 59 NM_003058
TATCTCCGCCCAACAAATC
OCT3 GGAGTTTCGCTCTGTTCAGG 216 55 NM_021977
GGAATGTGGACTGCCAAGTT
VAChT TACCCTACGGAGAGCGAAGA 157 59 U10554
CTGTAGAGGCGAACATGACG
βMG TCTCTCTTTCTGGCCTTGGAG 134 59 NM_004048
CAACTTCAATGTCGGATGGA
Table 2 Antibodies and blocking peptides used for single-stain immunohistochemistry (CHT high-affinity choline transporter,CTL choline transporter-
like, OCT organic cation transporter)
Primary antibody Peptide
Mouse anti-human CTL1 (1:100); Abgent (#AT3924a) CTL1 blocking peptide (200 μg/ml); Abgent (#BP14061c)
Mouse anti-human CTL2 (1:400); Acris (#AM21005PU-N) CTL2 recombinant protein (200 μg/ml); Acris (#H00057153-Q01)
Rabbit anti-rat CHT1 (1:10,000; Lips et al. 2002; 92 % homology to human) Rat CHT1 peptide (200 μg/ml; Lips et al. 2002)
Rabbit anti-human OCT1 (1:150); Aviva Systems
Biology (#ARP41516_T100)
OCT1 blocking peptide (200 μg/ml); Aviva
Systems Biology (#AAP41516)
Rabbit anti-rat OCT3 (1:300); Alpha Diagnostics
(#OCT31-A; 94 % homology to human)
OCT3 blocking peptide (200 μg/ml); Alpha Diagnostics (#OCT31-P)
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types, including non-neuronal (Uchida et al. 2009; Yabuki
et al. 2009) and neuronal (Machova et al. 2009; Yamada
et al. 2011) cells. Interestingly, CTL1 expression seems to be
regulated by extracellular choline availability, as choline de-
ficiency can lead to the down-regulation of this transporter
(Michel and Bakovic 2009). CTL2 has been shown to be
expressed in several tissues such as muscle, kidney, heart,
lung and the inner ear (Traiffort et al. 2013). Its role in choline
transport has recently been described for heterologously
expressed human CTL2 in Xenopus laevis oocytes
(Kommareddi et al. 2010) and in lung adenocarcinoma cells
(Nakamura et al. 2010). Expression of CTL3 has been found
in kidney, ileum, and colon, while CTL4 is predominantly
present in intestine, stomach, and kidney (Traiffort et al.
2005). Little is known about expression of CTL5, which has
been found to low extend in the brain and in the spinal cord
(Traiffort et al. 2013) and in small cell lung carcinoma cells,
where it has been shown to be involved in choline transport
(Song et al. 2013). Most interestingly, in cancer cells CTL4
does not only facilitate choline uptake but further seems to be
specifically linked to ACh synthesis and secretion, as knock
down of CTL4 resulted in a significant reduction of ACh
(Song et al. 2013). The efficient release of ACh is another
important factor characterizing a functional NNCS. In neuro-
nal cells, the vesicular ACh transporter (VAChT) is required
for ACh secretion. VAChT mediates the storage of ACh
vesicles from which ACh is quantally released (Erickson
Table 3 Antibodies used for double-stain immunohistochemistry with two mouse monoclonal primary antibodies (CTL choline transporter-like)
First primary antibody (blue) Second primary antibody (brown)
Mouse anti-human CD68 (Clone PGM1; 1:200); DAKO Mouse anti-human CTL1 (1:100)
Mouse anti-human CD163 (Clone EDHu-1; 1:200); AbD Serotec (#MCA1853T) Mouse anti-human CTL1 (1:100)
Mouse anti-human prolyl-4-hydroxylase-β (Clone 3-2B12; 1:80);
Acris (#AF0910-1)
Mouse anti-human CTL1 (1:100)
Mouse anti-human CTL2 (1:200) Mouse anti-human CD68 (Clone PGM1; 1:300)
Mouse anti-human CTL2 (1:200) Mouse anti-human CD163 (1:300)
Mouse anti-human CTL2 (1:200) Mouse anti-human prolyl-4-hydroxylase-β (Clone 3-2B12; 1:80)
Table 4 Antibodies used for double-stain immunohistochemistry with
mouse and rabbit primary antibodies (CarAT carnitin acetyltransferase,
CTL choline transporter-like)
Primary rabbit antibody (blue) Primary mouse
antibody (brown)
Rabbit anti-human CarAT (1:100); LSBio (#LS-
C167021/52635); preabsorption control with
blocking peptide (LS-E8292/40 – LSBio)
Mouse anti-human
CTL1 (1:100)
Rabbit anti-human CarAT (1:100); LSBio (#LS-
C167021/52635); preabsorption control with
blocking peptide (LS-E8292/40 – LSBio)
Mouse anti-human
CTL2 (1:400)
Rabbit anti-human von Willebrand factor
(1:10,000); Merck Millipore (#AB736)
Mouse anti-human
CTL2 (1:400)
Fig. 1 mRNA expression of the classical neuronal transporters CHT1
(high-affinity choline transporter 1) and VAChT (vesicular acetylcholine
transporter) in the human joint. a, b RT-PCR for CHT1 and VAChT
mRNA in synovial (a) and cartilage (b) samples from the hip of osteoar-
thritis (OA) and rheumatoid arthritis (RA) patients (lanes M 100 bp
ladder, lanes +RT+[reverse transcription with template], lanes −RT-
[RT without template]). SH-SY5Y (Sy) was used as a positive control
for VAChT expression and water (H2O) was employed instead of cDNA
as a negative control. c Representative RT-PCR for β2-microglobulin
(βMG) in samples of synovia (left) and cartilage (right) from the hip of
OA and RA patients
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et al. 1994). VAChT expression and vesicular storage and
release have only been reported in some non-neuronal cells
such as pancreatic α-cells (Rodriguez-Diaz et al. 2011), en-
dothelial cells (Kirkpatrick et al. 2001) and cardiomyocytes
(Rana et al. 2010). In most non-neuronal cholinergic cells,
ACh is not stored in vesicles but is directly released via
transporters. Of the family of organic cation transporters,
OCT1 and OCT2 have been revealed to be able to translocate
ACh out of the cell in the human airway (Lips et al. 2005),
whereas in the placenta, ACh release is mediated by OCT1
and OCT3 (Wessler et al. 2001). Recently, a new family of
OCTs, the organic cation transporters novel (OCTN), has been
identified in higher organisms (Eraly et al. 2004) and the
family member OCTN1 has been demonstrated to catalyze
the transport of ACh (Pochini et al. 2012). Further, the
mediatophore, a protein of 220 kDa consisting of 15-kDa
proteolipid subunits of the vacuolar H+-ATPase, is thought
to be involved in ACh exocytosis (Fujii et al. 2012; Israel and
Dunant 1998).
Evidence is increasing that the cholinergic system can play
an important role in the pathology of rheumatoid arthritis (RA;
Pan et al. 2010). Depending on mode, time-point and immune
status, the administration of nicotine has been shown to ame-
liorate experimental arthritis (Lindblad et al. 2009; van
Maanen et al. 2009; Yu et al. 2011). However, the role of the
α7 nicotinic receptor, which is known to function in the anti-
inflammatory cholinergic pathway (Tracey 2009), is still be-
ing discussed controversially in this regard (van Maanen et al.
2010; Westman et al. 2010).
In general, little is known about the NNCS in the human
joint. Grimsholm et al. in 2008 were able to show the
expression of ChAT and the α7 nicotinic receptor in synovial
tissue of the human knee joint in patients with RA and
osteoarthritis (OA). A study of our own group confirmed the
expression ofα7 nicotinic receptor, other subunits of nicotinic
receptors and various isotypes of muscarinic receptors (Schu-
bert et al. 2012) even though we could not clearly determine
the mRNA expression of ChAT, the ACh-synthsizing enzyme
CarATwas clearly detectable. With regard to choline and ACh
transporters, we could further identify the expression of OCT1
and OCT3 in the synovial tissue of the knee joints of RA and
OA patients.
In the present study, we analyze the expression of various
choline and ACh transporters, with special regard to the newly
discovered choline transporter-like proteins, in the human
joint. Even less information is available on the expression of
the NNCS in cartilage. Thus, in addition to the synovial tissue,




Synovial tissue and cartilage was obtained from RA and OA
patients at the time of hip joint replacement. All patients
fulfilled the criteria of the American College of Rheumatology
Classification for RA (Arnett et al. 1988) andOA (Altman et al.
1986). Written informed consent was obtained from all partic-
ipants. The study was performed according to the Declaration
of Helsinki and was approved by the local ethical committee.
Fig. 2 Expression of organic
cation transporter mRNA in the
human joint. a, b RT-PCR for
organic cation transporter 1-3
(OCT1-3) and organic cation
transporter novel (OCTN1)
mRNA in synovia (a) and
cartilage (b) from the hip of OA
and RA patients (lanes M 100 bp
ladder, lanes +RT+, lanes −RT-).
CaCo-2 cells (CC) were used as a
positive control for OCT2mRNA
expression and water (H2O) was
employed instead of cDNA
template as a negative control
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RNA isolation and qualitative reverse transcription plus
the polymerase chain reaction (RT-PCR)
Total RNAwas extracted from the samples by using the RNA
Lipid Tissue Mini Kit (Qiagen, Hilden, Germany). Removal
of genomic DNA contamination and subsequent reverse tran-
scription was performed with the Quantitect Kit (Qiagen)
according to the manufacture’s protocol. Reactions without
addition of reverse transcriptase were performed as controls
(reverse transcription negative, RT-). AmpliTaq Gold poly-
merase (Applied Biosystems, Darmstadt, Germany) was used
for cDNA amplification with gene-specific primers (Table 1;
MWG, Ebersberg, Germany). For electrophoretic separation,
RT-PCR products were subjected to 2 % TRIS-acetate-EDTA
agarose gel electrophoresis.
Real-time RT-PCR
Real-time RT-PCR analysis was performed by using gene-
specific primers (Table 1, MWG), SYBR Green PCR
Mastermix (Qiagen) and the I-Cycler IQTM5 detection system
(Bio-Rad, Munich, Germany). Standard and melt curves were
performed to determine PCR efficiency and specificity of
amplification, respectively. Mean cycle thresholds (Ct) values
were normalized to the reference gene β2-microglobulin
(βMG). Neuroblastoma cell line SH-SY5Y or colon carcino-
ma cell line CaCo-2 were used as positive controls.
Immunohistochemistry
Synovial tissue and cartilage samples were fixed in 4 %
phosphate-buffered paraformaldehyde (Merck, Darmstadt,
Germany). Before being embedded in paraffin, cartilage sam-
ples were demineralized in 0.281 M TRIS-buffer containing
10 % ethylene diamine tetra acetic acid (Merck). Sections of
3 μm in thickness were cut and deparaffinized in a decreasing
series of alcohols. For heat-induced antigen retrieval, sections
were subjected to pressure-cooking in citric buffer (pH 6.0)
for 15 min. After the blocking of endogenous peroxidase with
H2O2,, sections were incubated with 1 % bovine serum
Fig. 3 Expression of choline
transporter-like (CTL) protein
mRNA in the human joint. a, b
RT-PCR for CTL1-CTL5 mRNA
in synovia (a) and cartilage (b)
from the hip of OA and RA pa-
tients (lanes M 100 bp ladder,
lanes +RT+, lanes −RT-). c, d
Real-time RT-PCR for CTL1-
CTL5 mRNA in hip samples of
synovia (c) and cartilage (d) of
OA and RA patients (n = 5 each).
Data were normalized to refer-
ence geneβMGand are presented
as box plots with the median be-
ing indicated by a solid line within
the box
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albumin (BSA; Sigma Aldrich, Taufkirchen, Germany) and
10 % human serum (Sigma Aldrich) in phosphate-buffered
saline (PBS) for 30 min at room temperature.
Single-stain immunohistochemistry
Slides were incubated with the indicated primary antibody
(Table 2) in antibody diluent (Dako, Hamburg, Germany)
and 10 % human serum (Sigma Aldrich) overnight at 4 °C.
Sections were subjected to biotinylated rabbit anti-mouse
(1:150) or biotinylated goat anti-rabbit (1:800) secondary
antibody (both from Dako) diluted in PBS containing 1 %
BSA and 5 % human serum for 30 min at room tempera-
ture. After further treatment with Vectastain ABC Elite Kit
(Vector Laboratories, Burlingame, Calif., USA) according
to the manufacturer’s instructions, staining was visualized
by using Nova Red (Vector Laboratories). Counterstaining
was performed with hematoxylin and DePex (Serva,
Heidelberg, Germany) was used for cover-slipping. Nega-
tive controls were performed without incubation of the
primary antibodies and by using specific peptides (Table 2)
for preabsorption overnight at 4 °C. To test the specificity of the
antibodies further, Western blot analysis was performed (see
Electronic Supplementary Material). Sections were evaluated
with a photomicroscope (Axiophot-2, Zeiss, Jena, Germany)
equipped with a digital camera (DC500, Leica, Bensheim,
Germany).
Double-stain immunohistochemistry with two mouse
monoclonal primary antibodies
Primary antibodies were diluted in PBS containing 1 % BSA
and 10 % human serum and incubated with the sections
overnight at 4 °C. For detection of the first primary antibody
(Table 3), sections were incubated with rabbit anti-mouse IgG
(1:25; Dako) followed by monoclonal mouse alkaline
phosphatase/anti-alkaline phosphatase (APAAP; 1:25; Dako)
for 30 min at room temperature each. Bound alkaline phos-
phatase was visualized by using Fast Blue chromogen (Sigma
Aldrich). Antibodies were detached from the tissue by using
another step of pressure-cooking. Sections were treated again
for 30 min with 1 % BSA in PBS followed by overnight
incubation at 4 °C with the indicated second primary antibody
(Table 3). After incubation with peroxidase-labeled rabbit
anti-mouse antibody (1:70; Dako), staining was visualized
by using 3,3’ diaminobenzidine (DAB, Sigma Aldrich). Sec-
tions were cover-slipped with Kaiser’s glycerol gelatine
(Merck, Darmstadt, Germany). For control of staining, both
primary antibodies were omitted or each primary antibody
was omitted separately.
Double-stain immunohistochemistry with mouse and rabbit
primary antibodies
A mixture of mouse and rabbit primary antibodies (Table 4)
was diluted in antibody diluent (Dako) and incubated with the
Fig. 4 Immunohistochemical
localization of CTL1 and CTL2 in
the human joint. a, b
Immunohistochemical staining
for CTL1 in synovial tissue of the
hip joint of OA (a) and RA (b)
patients. Insert in a Preabsorption
control with specific CTL1
peptide. c, d
Immunohistochemical staining
for CTL2 in synovial tissue of the
hip joint of OA (c) and RA (d)
patients. Insert in c Preabsorption
control with specific CTL2
peptide
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sections overnight at 4 °C. After a 1-h treatment with alkaline-
phosphatase-labeled swine anti-rabbit antibody (1:30; Dako),
staining was visualized with Fast Blue chromogen. Subse-
quently, sections were incubated with biotinylated rabbit
anti-mouse secondary antibody (1:150; Dako) and staining
was visualized by using Vectastain ABC Elite Kit and DAB.
Kaiser’s glycerol gelatine was used for cover-slipping. For
control of staining, both antibodies were omitted or each
primary antibody was omitted separately.
Statistical analysis
SPSS software (SPSS Institute, Chicago, Ill., USA) was used
for statistical analysis. Delta Ct values were compared by the
global non-parametric rank-sum Kruskal-Wallis test. If signif-
icant (P ≤ 0.05), the Mann–Whitney test was used for further
analysis of statistical relevance.
Results
Classical neuronal components: CHT1 and VAChT
The classical neuronal choline transporter CHT1 was present
in the synovial tissue of patients with OA and RA (Fig. 1a). In
the joint cartilage, however, no CHT1 mRNA expression was
detectable in OA or RA patients (Fig. 1b). The mediator of
ACh storage in vesicles, VAChT, was neither expressed in
synovial tissue nor in cartilage samples of the human joint,
irrespective of pathology (Fig. 1a, b). PCR was controlled by
using neuroblastoma cell line SH-SY5Y as a VAChT-
expressing positive control (Fig. 1b). For every used sample,
PCR for βMG was performed to control RNA isolation
and cDNA synthesis; an example is shown in Fig. 1c
for synovial tissue and cartilage samples from patients
with OA and RA.
Fig. 5 CTL1 is expressed in
macrophage-like and fibroblast-
like synoviocytes. a, b Double-
staining for macrophage marker
CD68 (blue) and CTL1 (brown)
in synovial tissue. The boxed area
in a indicates the region shown at
higher magnification in b. c, d
Double-staining for macrophage
marker CD163 (blue) and CTL1
(brown) in synovial tissue. The
boxed area in c indicates the re-
gion shown at higher magnifica-
tion in d. e, f Double-staining for
prolyl-4-hydroxylase-β (P4H,
blue) and CTL1 (brown) in syno-
vial tissue. The boxed area in e
indicates the region shown at
higher magnification in f
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OCTs and OCTN1
In our previous study, we were able to show that OCT1 and
OCT3 were expressed in the synovial tissue of the knee joint
without showing a significant difference in expression levels
between samples from RA and OA patients (Schubert et al.
2012). In the synovia of the hip joint, we could detect both
transporters in samples from RA and from OA patients
(Fig. 2a). OCT1 and OCT3 mRNAwere also both present in
all analyzed cartilage samples of the joints (Fig. 2b), irrespec-
tive of OA or RA pathology. Moreover, for the transporter
OCTN1, mRNA expression was observed in synovial tissue
(Fig. 2a) and cartilage (Fig. 2b) from all patients. OCT2
mRNA, on the other hand, was detectable neither in synovial
tissue (Fig. 2a) nor in cartilage (Fig. 2b) of any investigated
sample.
CTL proteins
All five family members of the CTL proteins were present in
synovial tissue (Fig. 3a) and cartilage (Fig. 3b) of the human
joint. No difference in mRNA expression levels of any CTL
family member was observed between OA and RA patients by
real-time RT-PCR (Fig. 3c-d). In all analyzed samples, CTL1
and CTL2 mRNA were the most prominently expressed,
followed by CTL3 and by a lower expression of CTL4 and
CTL5 mRNA.
Fig. 6 CTL2 is expressed by synovial macrophages and fibroblasts and
by endothelial cells. a Single-staining for CTL2 in synovial tissue. The
boxed area indicates the area of staining that is represented in d. b, c
Double-staining for CTL2 (blue) and macrophage marker CD68 (brown)
in synovial tissue. The boxed area in b indicates the region shown at
higher magnification in c. e, f Double-staining for CTL2 (blue) and
macrophage marker CD163 (brown) in synovial tissue. The boxed area
in e indicates the region shown at higher magnification in f. d, g Double-
staining for CTL2 (blue) and fibroblast marker, prolyl-4-hydroxylase-β
(P4H, brown), in synovial tissue. The boxed area in d indicates the region
shown at higher magnification in g. h, i Double-staining for CTL2 and
endothelial cell marker, vonWillebrand factor (vWbF). The boxed area in
h indicates the region shown at higher magnification in i
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Little is known about the expression of CTL proteins in the
joint. Thus, we were further interested in the protein localiza-
tion of these choline transporters and performed immunohis-
tochemical staining for the two most prominently expressed
members, namely CTL1 and CTL2, in synovial tissue (Fig. 4).
CTL1 and CTL2 protein were shown to be present in the
synovial tissue of OA (Fig. 4a, c) and RA (Fig. 4b, d) patients
and staining was mainly observed in the synovial lining layer
but also in the subintimal layer. Double-staining of CTL1 with
macrophage markers CD68 and CD163 and with fibroblast
marker prolyl-4-hydroxylase-β localized the expression of this
transporter to macrophage-like (Fig. 5a-d) and fibroblast-like
(Fig. 5e, f) cells. Furthermore, the CTL2 protein was detected
in synovial macrophages (Fig. 6b, c, e, f) and fibroblasts
(Fig. 6d, g). Expression of CTL2 was further determined in
endothelial cells by using double-staining for the von
Willebrand factor (Fig. 6h, i). Moreover, the ACh-
synthesizing enzyme CarAT was also detectable in CTL1-
positive (Fig. 7b, c) and CTL2-positive (Fig. 7e, f) cells and
the staining pattern of these two CTL proteins (Fig. 7a, d) was
similar to that observed for CHT1 (Fig. 7g), OCT1 (Fig. 7h)
and OCT3 (Fig. 7i).
Discussion
In the present study, we were able to show that all necessary
components for the transport of choline into the cell and for
the release of ACh are present in the synovial tissue and
cartilage of the human hip joint (Fig. 8). At the mRNA
expression level, no differences between samples of OA or
RA origin are measurable, indicating that the pathological
state might not influence the transport of choline or ACh in
the human joint.
Fig. 7 CTL1- and CTL2-positive cells express the ACh-synthesizing
enzyme, carnitin acetyltransferase (CarAT). a Single-staining for CTL1 in
synovial tissue. b, cDouble-staining for CarAT (blue) and CTL1 (brown)
in synovial tissue. The boxed area in b indicates the region shown at
higher magnification in c. d Single-staining for CTL2 in synovial tissue.
e, fDouble-staining for CarAT (blue) and CTL2 (brown). The boxed area
in e indicates the region shown at higher magnification in f. g-i Single-
staining for CHT1 (g), OCT1 (h) and OCT3 (i) on synovial tissue
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This is the first time that all members of the recently
described family of CTL proteins have been shown to be
expressed in the synovial tissue and cartilage of the human
joint. CTL1, the best characterizedmember of the CTL family,
is expressed the most prominently in both synovia and carti-
lage. This is in accordance with other tissues and cells such as
keratinocytes in which CTL1 expression has also been found
to be more pronounced than that of other CTL proteins
(Uchida et al. 2009). We have been able to localize CTL1
protein expression tomacrophage-like and fibroblast-like cells
of the synovial tissue. As the specificity of CD68 as a macro-
phage marker has been critically discussed, we additionally
chose to use CD163 to label macrophage-like synoviocytes in
the tissue (Fonseca et al. 2002; Kunisch et al. 2004; Lau et al.
2004). Our finding is consistent with previous studies that
identified CTL1 as being a constitutively expressed cell sur-
face antigen onmonocytic cells (Wille et al. 2001). Regulation
of CTL1 in immune cells has only been reported for dendritic
cells, as activation with calcium ionophores in these cells
leads to the down-regulation of CTL1 (Wille et al. 2001).
Further, human CTL1 has been shown to be up-regulated in
several cancer cell lines (Wang et al. 2007) in myopathies and
leukemias (Yuan et al. 2006). In the present study, however,
no significant difference in CTL1 expression was observed
between joints of OA and RA patients. For the human CTL1
gene, two splice variants have been characterized, encoding
two proteins differing in a C-terminal peptide (Yuan et al.
2006). However, the specific roles and significance of the
two CTL1 isoforms still have to be analyzed. Thus, in the
present study, we used primers amplifying both transcript
variants.
CTL2 was first discovered in the supporting cells of
the inner ear (Zajic et al. 1991) and antibodies against
CTL2 are reported to cause hair cell death and hearing
loss (Nair et al. 2004). Notably, antibodies against
CTL2 have been detected in 50 % of patients with
autoimmune hearing loss (Kommareddi et al. 2009)
indicating a prominent role of CTL2 in this and possi-
bly other autoimmune diseases. Interestingly, a single
nucleotide polymorphism in the CTL2 gene has been
reported to encode for the human neutrophil alloantigen
(HNA)-3a, which represents the target antigen for
antibody-mediated transfusion-related acute lung injury
(Curtis et al. 2010; Greinacher et al. 2010). In the
human hip joint, we were able to localize CTL2 in
macrophage-like and fibroblast-like cells and in endo-
thelial cells of the synovial tissue. The latter finding is
in accordance with previous studies in which CTL2
expression has been found in monocytes and endothelial
cells (Flesch et al. 2013). No expression differences
between joints of OA and RA patients have been ob-
served. As for CTL1, alternative splicing results in two
isoforms of the CTL2 protein differing in the first 12
amino acids of presumably the cytoplasmic N-terminus
(Nair et al. 2004) and in one isoform that differs in its
C-terminus and that might be epithelial-cell-specific
(Kommareddi et al. 2010). To date, whether the various
isoforms can exert diverse functions is unclear and thus,
in the present study, we first took a general look at
CTL2 expression by choosing primers amplifying all
isoforms.
We were able to show that the other family members,
namely CTL3, CTL4 and CTL5, are also expressed, though
to a lesser extent, in synovial tissue and cartilage of the human
joint. However, little is known about the functionality of these
three transporters (Inazu 2014). Interestingly, CTL4 mRNA
expression, which has been shown to be related to the synthe-
sis and release of non-neuronal ACh in cancer cells (Song
et al. 2013), is detectable in all analyzed samples, indicating a
possible role of this transporter for ACh release also in the
human joint.
From the family of polyspecific OCTs, both OCT1 and
OCT3mRNA are expressed in cartilage and in synovia of the
human joint, whereas OCT2 is not detectable in any analyzed
sample. This observation is consistent with other studies
reporting that OCT1 and OCT3 show a rather broad tissue
expression pattern, whereas the distribution of OCT2 seems to
be more restricted (Inazu 2014; Koepsell et al. 2007). The
transporter OCTN1 has been shown to be expressed in a
variety of tissues, especially immune-related tissue, such as
Fig. 8 Representation of the expression of choline and acetylcholine
transporters in the human joint. The transporters CTL1-5, OCT1,
OCT3, and OCTN1 are expressed in the synovia and the cartilage of
the human joint. The classic neuronal choline transporter CHT1 is only
expressed in synovial tissue, and not in the cartilage of the joint
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spleen and bone marrow and in several immune cell types
(Koepsell et al. 2007; Tokuhiro et al. 2003). Tokuhiro et al.
(2003) reported that OCTN1 is expressed in synovial tissue
of RA patients and in arthritic mice, whereas OCTN1
expression has not been observed non-arthritic control
mice. Further, the induction of OCTN1 mRNA expres-
sion has been observed in human synovial fibroblasts
isolated from RA patients after stimulation with tumor-
necrosis factor-alpha (Tokuhiro et al. 2003). We were
able to confirm the expression of OCTN1 in the syno-
vial tissue of the hip joint of RA patients; however, in
OA patients serving as the non-inflammatory control,
the expression of OCTN1 is also detectable. The same
can be observed for the analyzed cartilage samples in
our study. Most interestingly, an association between
functional variants of the OCTN1 gene and RA has
been reported in the Japanese population leading to
the hypothesis that the small nuclear polymorphism
(SNP) in intron 1 of the OCTN1 gene lowers the affinity for
the Runt-related transcription factor 1 (RUNX1), which regu-
lates OCTN1 expression (Tokuhiro et al. 2003). However, the
identification of OCTN1 as an RA susceptibility gene could
not be verified in the Canadian (Newman et al. 2005), UK
(Barton et al. 2005), or Spanish (Martinez et al. 2006; Orozco
et al. 2006) population and could not be reproduced by an-
other group working on the Japanese population (Kuwahara
et al. 2005).
Taken together, these data suggest that the import of
choline for ACh synthesis is facilitated mainly by OCT1
and members of the CTL family in the synovial tissue
and cartilage of the human joint. In synovial tissue but
not cartilage, the classic neuronal component CHT1
might also contribute to this process. The transport of
ACh out of synovial or cartilage cells occurs directly
and not via vesicles, as no VAChT expression is detect-
able. Members of the OCT family and CTL4 and
OCTN1 might be responsible for mediating this direct
release of ACh. In the synovial tissue, the transporters
CTL1 and CTL2 have been localized to macrophage-
like and fibroblast-like cells and other transporters show
a similar expression pattern in this tissue. The presence
of the ACh-synthesizing enzyme CarAT in cells express-
ing CTL1 and CTL2 provides a hint that these non-
neuronal synovial cells produce ACh. Thus, all impor-
tant components for the synthesis and release of ACh
are present in the synovial tissue and cartilage of the
human joint but no differences between OA and RA
pathology are detectable.
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